DS
CBIO

David Shaw’s Crescent Biopharma CBIO Stock Holding History

David Shaw’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-366
Closed -$20K – 4947
2022
Q3 		$20K Sell
366
-2,054
-85% -$148K ﹤0.01% 4805
2022
Q2 		$144K Sell
2,420
-137
-5% -$10.1K ﹤0.01% 4657
2022
Q1 		$291K Sell
2,557
-122
-5% -$14.3K ﹤0.01% 4663
2021
Q4 		$385K Sell
2,679
-489
-15% -$88.7K ﹤0.01% 4546
2021
Q3 		$694K Buy
3,168
+513
+19% +$109K ﹤0.01% 3873
2021
Q2 		$616K Sell
2,655
-2,504
-49% -$637K ﹤0.01% 3922
2021
Q1 		$1.55M Sell
5,159
-617
-11% -$221K ﹤0.01% 2794
2020
Q4 		$2.17M Buy
5,776
+1,719
+42% +$602K ﹤0.01% 2504
2020
Q3 		$1.25M Buy
4,057
+64
+2% +$24.5K ﹤0.01% 2717
2020
Q2 		$1.5M Buy
3,993
+2,060
+107% +$583K ﹤0.01% 2629
2020
Q1 		$440K Buy
1,933
+1,151
+147% +$440K ﹤0.01% 3272
2019
Q4 		$414K Buy
782
+290
+59% +$157K ﹤0.01% 3490
2019
Q3 		$212K Buy
+492
New +$316K ﹤0.01% 3605
2018
Q2 		– Sell
-109
Closed -$177K – 3760
2018
Q1 		$177K Sell
109
-1,416
-93% -$2.94M ﹤0.01% 3349
2017
Q4 		$2.56M Buy
+1,525
New +$2.02M ﹤0.01% 1955

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

David Shaw's CBIO Position: Q4 2022 in Review

David Shaw sold out of Crescent Biopharma (CBIO) in Q4 2022, closing a stake of 366 shares — an estimated $20K sold.

David Shaw first reported a position in CBIO in Q4 2017 and held it in 15 quarters. The position peaked at $2.56M in Q4 2017. 48 funds tracked by Wall St. Rank hold CBIO as of Q4 2022.

  • David Shaw reported no remaining Crescent Biopharma position as of Q4 2022 after selling out during the quarter.
  • David Shaw sold 366 Crescent Biopharma shares in Q4 2022, an estimated $20K.
  • David Shaw first reported a position in Crescent Biopharma in Q4 2017 and held it in 15 quarters.
  • David Shaw's Crescent Biopharma position peaked at $2.56M in Q4 2017.
  • 48 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2022.

Based on D.E. Shaw & Co's 13F filing for Q4 2022, filed 14 Feb 2023.